How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,634 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13941. Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer

Creatinine clearance at least 50 mL/min Calcium normal Cardiovascular No symptomatic coronary artery disease (angina) No myocardial infarction within the past 6 months Other No other invasive malignancy within the past 3 years except nonmelanoma skin cancer No simultaneous primary tumors Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy Endocrine therapy (...) fractionation radiation therapy Procedure: Conventional surgery for select patients Phase 3 Detailed Description: OBJECTIVES: Primary Compare overall survival of patients with stage III or IV squamous cell carcinoma of the head and neck treated with conventional vs accelerated radiotherapy and concurrent cisplatin with or without surgical resection. Secondary Compare local-regional control of disease and disease-free rates in patients treated with these regimens. Compare the acute and late toxicity

2002 Clinical Trials

13942. Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

within the past 3 years except squamous cell or basal cell skin cancer or other curatively treated malignancy PRIOR CONCURRENT THERAPY: Biologic therapy: Must have prior vaccinia for smallpox immunization No other concurrent biologic therapy Chemotherapy: No prior chemotherapy for prostate cancer No concurrent chemotherapy Endocrine therapy: See Disease Characteristics At least 4 weeks since prior hormonal therapy (6 weeks for bicalutamide) and recovered If disease progression on LHRH antagonist (...) : Completed First Posted : January 27, 2003 Last Update Posted : April 29, 2015 Sponsor: National Cancer Institute (NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate

2001 Clinical Trials

13943. Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

of undiagnosed non-occult, non-hemorrhoidal gastrointestinal or other bleeding sources within the past 6 months) No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer that is currently in complete remission HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study PRIOR CONCURRENT (...) recurrent squamous cell carcinoma of the larynx stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity recurrent salivary gland cancer salivary gland squamous cell carcinoma stage IV salivary gland cancer Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma, Squamous Cell Head and Neck Neoplasms Thromboembolism Squamous Cell Carcinoma of Head and Neck Carcinoma Neoplasms, Glandular and Epithelial

2001 Clinical Trials

13944. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

Keywords provided by Fox Chase Cancer Center: stage 0 esophageal cancer stage I esophageal cancer stage II esophageal cancer stage III esophageal cancer squamous cell carcinoma of the esophagus adenocarcinoma of the esophagus Additional relevant MeSH terms: Layout table for MeSH terms Esophageal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases Paclitaxel Albumin (...) a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma, squamous cell, adenosquamous, or undifferentiated carcinoma of the esophagus or gastroesophageal junction

2001 Clinical Trials

13945. Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer

: Bilirubin no greater than 1.5 times upper limit of normal (ULN) AST and ALT no greater than 5 times ULN PT/aPTT no greater than 1.2 times ULN Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance at least 50 mL/min No impaired renal function Cardiovascular: No impaired cardiac function Other: No active infection No other malignancy within the past 5 years except basal cell or squamous cell skin cancer Not pregnant or nursing Negative pregnancy test Fertile patients must use effective (...) , not recruiting First Posted : September 10, 2003 Last Update Posted : August 2, 2013 Sponsor: Jonsson Comprehensive Cancer Center Collaborator: National Cancer Institute (NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of tocladesine in treating patients who have recurrent

2001 Clinical Trials

13946. Radiation Therapy in Treating Patients With Head and Neck Cancer

cavity stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity salivary gland squamous cell carcinoma stage I salivary gland cancer stage II salivary gland cancer stage III salivary gland cancer stage IV salivary gland cancer Additional relevant MeSH terms: Layout table for MeSH terms Head and Neck Neoplasms Skin Neoplasms Neoplasms by Site Neoplasms Skin Diseases (...) Study Description Go to Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy is more effective for head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of radiation therapy in treating patients who have head and neck cancer. Condition or disease Intervention/treatment Phase Head and Neck Cancer Non-melanomatous Skin Cancer Procedure: adjuvant therapy

2001 Clinical Trials

13947. Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

No ventricular dysrhythmia No active unresolved infection requiring parenteral antibiotics within the past week No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or clinically unsuspected organ-confined prostate cancer treated with prior prostatectomy Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No prior systemic biologic response modifier therapy See Disease (...) Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: Phase II trial to study the effectiveness of ixabepilone in treating patients who have progressive or metastatic urinary tract cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Condition or disease Intervention/treatment Phase Distal Urethral Cancer Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter Proximal Urethral Cancer Recurrent Bladder

2001 Clinical Trials

13948. Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer

of the oral cavity stage IV mucoepidermoid carcinoma of the oral cavity recurrent squamous cell carcinoma of the lip and oral cavity recurrent basal cell carcinoma of the lip Additional relevant MeSH terms: Layout table for MeSH terms Head and Neck Neoplasms Uterine Cervical Neoplasms Esophageal Neoplasms Anus Neoplasms Vulvar Neoplasms Penile Neoplasms Neoplasms by Site Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Uterine Cervical Diseases Uterine Diseases Genital Diseases (...) ) Study Details Study Description Go to Brief Summary: RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients who have advanced or recurrent cancer of the cervix, vagina, penis, anus, esophagus, or head and neck. Condition or disease Intervention/treatment Phase Anal Cancer Cervical Cancer Esophageal Cancer Head and Neck Cancer

2001 Clinical Trials

13949. Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

: Ejection fraction at least 45% by MUGA No uncontrolled or significant cardiovascular disease No myocardial infarction within the past year No significant congestive heart failure Pulmonary: FEV_1 at least 60% predicted DLCO at least 60% predicted FVC at least 60% predicted Other: No other malignancy except curatively treated squamous cell carcinoma in situ of the cervix or basal cell skin cancer No other serious medical or psychiatric illness that would preclude study participation HIV negative (...) Center ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000068797 RWMC-0633846 First Posted: January 27, 2003 Last Update Posted: May 5, 2015 Last Verified: May 2015 Keywords provided by Roger Williams Medical Center: stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Cyclophosphamide Doxorubicin Liposomal

2001 Clinical Trials

13950. Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer

ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin-epinephrine injectable gel plus paclitaxel and carboplatin in treating patients who have recurrent head and neck cancer. Condition or disease Intervention/treatment Phase Head and Neck Cancer Drug: carboplatin Drug: cisplatin-e therapeutic implant Drug: paclitaxel Phase 2 Detailed Description: OBJECTIVES: I. Determine the antitumor activity of intratumoral cisplatin-epinephrine injectable gel (...) cell carcinoma of the head and neck The following other histological types are also eligible: Epithelial carcinoma Verrucous carcinoma Sarcomatoid squamous cell carcinoma Lymphoepithelioma Pseudosarcoma Anaplastic carcinoma Transitional cell carcinoma At first relapse after prior definitive surgery, radiotherapy, and/or chemotherapy and not a candidate for potentially curative salvage surgery or salvage radiotherapy Relapsed or metastatic disease in one of the following primary head and neck areas

2001 Clinical Trials

13951. Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

Institute (NCI): adenocarcinoma of unknown primary squamous cell carcinoma of unknown primary undifferentiated carcinoma of unknown primary newly diagnosed carcinoma of unknown primary Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Neoplasms, Unknown Primary Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasm Metastasis Neoplastic Processes Pathologic Processes Cisplatin Cyclophosphamide Doxorubicin Fluorouracil Vincristine Epirubicin Liposomal (...) No squamous cell carcinoma in cervical lymph nodes as sole site of disease in male or female patients No neuroendocrine tumors No elevated alpha-fetoprotein, beta-HCG, or PSA PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: More than 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin less than 1.8 mg/dL Renal: Creatinine less than 1.5

2001 Clinical Trials

13952. Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer

of the oropharynx skin metastases Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma, Squamous Cell Head and Neck Neoplasms Neoplasm Metastasis Squamous Cell Carcinoma of Head and Neck Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Neoplasms by Site Neoplastic Processes Pathologic Processes Vaccines Immunologic Factors Physiological Effects of Drugs (...) ) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer. Condition or disease Intervention/treatment Phase Head and Neck Cancer Metastatic Cancer Biological: recombinant fowlpox-TRICOM vaccine Phase 1 Detailed Description: OBJECTIVES

2001 Clinical Trials

13953. RPI.4610 in Treating Patients With Metastatic Kidney Cancer

York Heart Association class III or IV heart disease No uncontrolled hypertension, defined as newly diagnosed but untreated or treated but with diastolic blood pressure at least 95 mmHg or systolic blood pressure at least 160 mmHg Other: HIV negative No systemic infection requiring antibiotics within the past 28 days No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No alcohol or drug abuse within the past 2 years No other (...) : CDR0000068739 UCLA-001201501 RPI-0004 NCI-G01-1975 First Posted: February 16, 2004 Last Update Posted: March 26, 2013 Last Verified: May 2002 Keywords provided by National Cancer Institute (NCI): stage IV renal cell cancer clear cell renal cell carcinoma Additional relevant MeSH terms: Layout table for MeSH terms Kidney Neoplasms Carcinoma, Renal Cell Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Kidney Diseases Urologic Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular

2001 Clinical Trials

13954. Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

engaging in reproductive activity with women of child-bearing potential throughout the course of study treatment and for 4 weeks following the discontinuation of study treatment. May have had only one prior regimen of chemotherapy for prostate cancer. The chemotherapy must have been stopped at least 4 weeks prior to study entry. Disease-free of other malignancies for greater than 5 years with the exception of curatively treated basal cell, squamous cell carcinoma of the skin of Ta transitional cell (...) form. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret data from the study. Use of any other experimental drug or therapy within 28 days of baseline. Any prior use of CC-4047 of Thalidomide Tumors containing small cell or sarcomatoid elements Symptomatic bone metastases. Concurrent use of any other anti-cancer agents. Known brain disease that is symptomatic

2003 Clinical Trials

13955. Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

No peripheral sensory neuropathy No known sensitivity to celecoxib, other COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides No AIDS-related illness No active infection No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy No prior (...) of colorectal cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Combining chemotherapy with celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining celecoxib with leucovorin, fluorouracil, and oxaliplatin in treating patients who have metastatic colorectal cancer. Condition or disease Intervention/treatment Phase Colorectal Cancer Drug: celecoxib Drug: fluorouracil Drug: leucovorin calcium Drug: oxaliplatin

2003 Clinical Trials

13956. Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer

Glomerular filtration rate ≥ 30 mL/min Other Not pregnant or nursing Fertile participants must use effective contraception Able to undergo adequate mammography and cooperate with breast ultrasound No concurrent medical or psychiatric condition that would preclude biopsy No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No contraindications to MRI (e.g., pacemaker, aneurysm clip, or other implanted magnetic device (...) information ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000339812 ACRIN-6666 First Posted: November 6, 2003 Last Update Posted: October 30, 2012 Last Verified: February 2006 Keywords provided by National Cancer Institute (NCI): breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases

2003 Clinical Trials

13957. Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases

Not specified Hematopoietic Not specified Hepatic See Disease Characteristics Renal Not specified Other Not pregnant or nursing No other prior or concurrent malignancy except the following: Adequately treated basal cell or squamous cell skin cancer Adequately treated carcinoma in situ of the cervix Adequately treated in situ melanoma Contralateral or ipsilateral carcinoma in situ of the breast No psychiatric, addictive, or other disorder that may compromise ability to give informed consent Geographically (...) -negative breast cancer estrogen receptor-positive breast cancer progesterone receptor-negative breast cancer progesterone receptor-positive breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasm Micrometastasis Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Neoplasm Metastasis Neoplastic Processes Pathologic Processes Progesterone Estrogens Progestins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

2003 Clinical Trials

13958. Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer

confirmed squamous cell carcinoma or adenocarcinoma of the thoracic esophagus, including the gastroesophageal junction (Siewert type I) Locally advanced disease that is technically operable with curative intent (R0) T3, N0 OR T1-3, N+ OR T4, NX No T1-2, N0 No inoperable T4 (unequivocal organ involvement) No distant metastasis, including M1a lymph node status Lymph nodes suspicious of M1a status by CT scan, PET scan, or ultrasound must be verified by fine-needle aspiration cytology No carcinoma (...) No preexisting peripheral neuropathy greater than grade 1 No uncontrolled diabetes mellitus No active autoimmune disease No other serious medical condition that would preclude study participation No other prior or concurrent malignancy except nonmelanoma skin cancer or adequately treated carcinoma in situ of the cervix No significant neurologic or psychiatric disorder, including psychotic disorders, dementia, or seizures that would preclude comprehension and ability to provide informed consent and complete

2003 Clinical Trials

13959. Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

bone scan or measurable disease). Progressive disease after androgen deprivation. No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control prostate cancer). Exclusion Criteria: Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been disease-free for greater than or equal to 5 years. Previous occurrence of autoimmune disease. Active infection (...) (docetaxel) in combination with MDX-010 Condition or disease Intervention/treatment Phase Prostate Cancer Drug: MDX-010 / MDX-010 + Docetaxel Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomized Study Comparing 4 Monthly Doses of MDX-010 (CTLA-4) as a Single Agent or Used in Combination With a Single Dose

2002 Clinical Trials

13960. Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

illness No other malignancy within the past 3 years except squamous cell or basal cell skin cancer No history of seizures, encephalitis, or multiple sclerosis No active inflammatory bowel disease Must be able to avoid close household contact with the following during and for 2 weeks after vaccinations: Persons with active or prior eczema or other eczematoid skin disorders Persons with any other acute, chronic, or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella zoster (...) dividing so they stop growing or die. Combining vaccine therapy with sargramostim and chemotherapy may kill more tumor cells. PURPOSE: Randomized clinical trial to study the effectiveness of vaccine therapy plus sargramostim and combination chemotherapy in treating women who have undergone surgery for stage II or stage III breast cancer that has spread to the lymph nodes. Condition or disease Intervention/treatment Phase Breast Cancer Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine Biological

2003 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>